Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio presented 6-to-9-month clinical data from the lowest dose cohort of rese-cel in the RESET-PV study, showing compelling drug-free clinical responses in half of pemphigus vulgaris patients without preconditioning. The company also announced a 10-year commercial supply agreement with Cellares, which aims to produce rese-cel for thousands of patients per year at a low cost of goods with minimal capital investment. Cabaletta raised $150 million in gross proceeds from a registered direct offering, including participation from major investors such as Eli Lilly and Company, Bain Capital Life Sciences, Adage Capital Management, and Cormorant Asset Management.
Key figures
- Net Loss
- 43515000
- Cash And Equivalents
- 116635000
- Research And Development Expenses
- 37353000
- General And Administrative Expenses
- 6943000
- Deal Value Usd
- 150000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.